Tradestie Institutional Equity Comparison Engine
AUTL vs EVMN โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
EVMN Overall Edge
EVMN Captures Institutional Edge (3โ0 Pillars ยท 4โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Evommune, Inc. (EVMN) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, AUTL trades at N/M Forward P/E with -159.3% operating margin (+94.6% YoY revenue) versus EVMN at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, AUTL sits in UNCLASSIFIED (<1st %ile IV; Dealer Gamma Walls on Pro) against EVMN sits in SURGE (53rd %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
AUTL N/M vs EVMN N/M Fwd P/E
Growth & Margin Winner
EVMN
Op Margin -159.3% vs 0.0% ยท YoY +94.6% vs +0.0%
Momentum & Technical Winner
EVMN
1Y -10.9% vs -61.0% ยท 52W Pos 5% vs 8%
Options & Structure Winner
EVMN
UNCLASSIFIED (<1st %ile IV) vs SURGE (53rd %ile IV)
AUTL
NASDAQ
Autolus Therapeutics plc American Depositary Share
Biological Products, (No Disgnostic Substances)
$1.14
-2.56% 1D
Market Cap
$311.4M
1M Return
-28.75%
1Y Return
-10.94%
Forward P/E
N/M
Unified AI Score
40.4 / 100
SELL
Tech 25.0
Fund 42.0
Flow 50.0
Mom 40.0
EVMN
US Equity
Evommune, Inc.
Pharmaceutical Preparations
$7.10
-6.95% 1D
Market Cap
$315.5M
1M Return
+37.33%
1Y Return
-61.03%
Forward P/E
N/M
Unified AI Score
30.0 / 100
SELL
Tech 50.0
Fund 35.0
Flow 69.0
Mom 44.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
AUTL -10.94%
EVMN -61.03%
Spread: +50.09 pp (AUTL Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
AUTL TTM Op. Margin: -159.3%
EVMN TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AUTL vs EVMN. Trailing 12-month operating profitability (AUTL -159.3% vs EVMN 0.0%) and valuation multiples (AUTL N/M vs EVMN N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | AUTL | EVMN | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $311.4M | $315.5M | Larger Scale | Tie |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +94.6% | +0.0% | Higher Growth | AUTL |
| Operating Margin (TTM) Profitability | -159.3% | 0.0% | Higher Margin | EVMN |
| Net Profit Margin Profitability | -186.4% | 0.0% | Higher Margin | EVMN |
| Return on Equity (ROE) Capital Efficiency | -174.9% | -69.5% | Higher ROE | EVMN |
| 52-Week Range Position Momentum | 5% ($1โ$3) | 8% ($5โ$33) | Stronger Trend | EVMN |
| Beta / 30D Volatility Risk Regime | 1.66ฮฒ ยท 55% Vol | 1.05ฮฒ ยท 118% Vol | Lower Realized Risk | AUTL |
| Unified Institutional Score Composite Signal | 40.4 / 100 (SELL) | 30.0 / 100 (SELL) | Higher Composite | AUTL |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full AUTL vs EVMN Buy Guide
AUTL
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
<1st %ile
IV Regime
Compressed (<25th %ile)
EVMN
SURGE
5d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
53rd %ile
IV Regime
Balanced (25thโ60th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither AUTL nor EVMN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.